Pyxis Oncology (NASDAQ:PYXS) Coverage Initiated by Analysts at Wedbush

Key Points

• Wedbush initiated coverage with an "outperform" rating and a $6.00 price target, implying roughly a 240.9% upside from the prior close.
• Consensus among analysts is a "Moderate Buy" (six Buys, one Hold, one Sell) with an average price target of $6.83, indicating an overall bullish tilt despite divergent views.
• Shares trade near $1.76 (market cap ≈ $110.6M); Pyxis beat quarterly estimates with EPS of -$0.29 vs. -$0.35 expected and revenue of $11.04M vs. $0.13M expected, and institutional investors now own about 39% of the stock.

Investment analysts at Wedbush initiated coverage on shares of Pyxis Oncology (NASDAQ:PYXS - Get Free Report) in a report issued on Tuesday. The brokerage set an "outperform" rating and a $6.00 price target on the stock. Wedbush's price target indicates a potential upside of 240.91% from the company's previous close.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Stifel Nicolaus reduced their target price on Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, March 24th. HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Tuesday, March 24th. Finally, Wall Street Zen raised Pyxis Oncology from a "sell" rating to a "hold" rating in a report on Monday, April 13th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $6.83.

Pyxis Oncology Trading Up 2.3%

Shares of PYXS opened at $1.76 on Tuesday. The firm has a market cap of $110.58 million, a PE ratio of -1.36 and a beta of 1.43. The company's 50 day simple moving average is $1.55 and its 200-day simple moving average is $2.36. Pyxis Oncology has a 12-month low of $0.97 and a 12-month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The firm had revenue of $11.04 million during the quarter, compared to analysts' expectations of $0.13 million. As a group, equities research analysts forecast that Pyxis Oncology will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC raised its stake in Pyxis Oncology by 1,939.3% in the 4th quarter. Barclays PLC now owns 60,385 shares of the company's stock valued at $69,000 after purchasing an additional 57,424 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Pyxis Oncology by 37.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company's stock valued at $58,000 after purchasing an additional 13,550 shares during the last quarter. HRT Financial LP raised its stake in Pyxis Oncology by 157.5% in the 4th quarter. HRT Financial LP now owns 39,649 shares of the company's stock valued at $45,000 after purchasing an additional 24,251 shares during the last quarter. XTX Topco Ltd acquired a new position in Pyxis Oncology in the 2nd quarter valued at about $40,000. Finally, LPL Financial LLC raised its stake in Pyxis Oncology by 150.7% in the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company's stock valued at $40,000 after purchasing an additional 21,100 shares during the last quarter. Institutional investors and hedge funds own 39.07% of the company's stock.

About Pyxis Oncology

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.